As FDA lifts clinical hold on its $4.9B CD47 drug, Gilead talks 2023 readout, ‘unwavering’ confidence – Endpoints News
Almost each medical trial, no matter indication or section, ought to be agile—incorporating expertise and decentralized approaches—to make drug and ...
